-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, OfPkuBuDJ8S5wgRRbO0wpW266aYyLhs+MyYSkUjJPbhFkTrWo+Mk7ml99pbXppda Ro/5Jh9Im+q6DI3l1CF80Q== 0000947871-06-001016.txt : 20060526 0000947871-06-001016.hdr.sgml : 20060526 20060526113415 ACCESSION NUMBER: 0000947871-06-001016 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20060526 DATE AS OF CHANGE: 20060526 GROUP MEMBERS: MERLIN BIOMED GROUP LLC GROUP MEMBERS: MERLIN BIOMED LONG TERM APPRECIATION, LLC GROUP MEMBERS: MERLIN BIOMED OFFSHORE MASTER FUND SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: TAPESTRY PHARMACEUTICALS, INC CENTRAL INDEX KEY: 0000891504 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 841187753 STATE OF INCORPORATION: DE FISCAL YEAR END: 1228 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-49101 FILM NUMBER: 06869357 BUSINESS ADDRESS: STREET 1: 4840 PEARL EAST CIRCLE STREET 2: SUITE 300W CITY: BOULDER STATE: CO ZIP: 80301 BUSINESS PHONE: 303-516-8500 MAIL ADDRESS: STREET 1: 4840 PEARL EAST CIRCLE STREET 2: SUITE 300W CITY: BOULDER STATE: CO ZIP: 80301 FORMER COMPANY: FORMER CONFORMED NAME: NAPRO BIOTHERAPEUTICS INC DATE OF NAME CHANGE: 19940421 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: MERLIN BIOMED GROUP LLC CENTRAL INDEX KEY: 0001106843 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: 237 PARK AVE STREET 2: STE 801 CITY: NEW YORK STATE: NY ZIP: 10017 BUSINESS PHONE: 2128087425 MAIL ADDRESS: STREET 1: 237 PARK AVE STREET 2: STE 801 CITY: NEW YORK STATE: NY ZIP: 10017 SC 13G 1 sc13g_052506-tapestry.txt RULE 13D-1(C) U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Tapestry Pharmaceuticals, Inc. ------------------------------------------------ (Name of Issuer) Common Stock ------------------------------------------------ (Title of Class of Securities) 876031204 ------------------------------------------------ (CUSIP Number) April 5, 2006 ----------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ] Rule 13d-1(b) [X] Rule 13d-1(c) [ ] Rule 13d-1(d) The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). 1 CUSIP No. 876031204 - -------------------------------------------------------------------------------- 1) Names of Reporting Persons I.R.S. Identification Nos. of Above Persons (Entities Only) Merlin BioMed Long Term Appreciation, LLC (54-2089246) - -------------------------------------------------------------------------------- 2) Check The Appropriate Box If a Member of a Group (See Instructions) (A) [ ] (B) [ ] - -------------------------------------------------------------------------------- 3) SEC Use Only - -------------------------------------------------------------------------------- 4) Citizenship or Place of Organization Delaware Limited Partnership - -------------------------------------------------------------------------------- Number of Shares Beneficially Owned by Each Reporting Person With: 5) Sole Voting Power 0 ----------------------------------------------- 6) Shared Voting Power 350,000 ----------------------------------------------- 7) Sole Dispositive Power 0 ----------------------------------------------- 8) Shared Dispositive Power 350,000 - -------------------------------------------------------------------------------- 9) Aggregate Amount Beneficially Owned by Each Reporting Person 350,000 - -------------------------------------------------------------------------------- 10) Check If the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] - -------------------------------------------------------------------------------- 11) Percent of Class Represented by Amount in Row (9) 2.0% - -------------------------------------------------------------------------------- 12) Type of Reporting Person (See Instructions) OO 2 CUSIP No. 876031204 1) Names of Reporting Persons I.R.S. Identification Nos. of Above Persons (Entities Only) Merlin BioMed Offshore Master Fund (98-0416713) - -------------------------------------------------------------------------------- 2) Check The Appropriate Box If a Member of a Group (See Instructions) (A) [ ] (B) [ ] - -------------------------------------------------------------------------------- 3) SEC Use Only - -------------------------------------------------------------------------------- 4) Citizenship or Place of Organization Cayman Islands Partnership - -------------------------------------------------------------------------------- Number of Shares Beneficially Owned by Each Reporting Person With: 5) Sole Voting Power 0 ----------------------------------------------- 6) Shared Voting Power 650,000 ----------------------------------------------- 7) Sole Dispositive Power 0 ----------------------------------------------- 8) Shared Dispositive Power 650,000 - -------------------------------------------------------------------------------- 9) Aggregate Amount Beneficially Owned by Each Reporting Person 650,000 - -------------------------------------------------------------------------------- 10) Check If the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] - -------------------------------------------------------------------------------- 11) Percent of Class Represented by Amount in Row (9) 4.0% - -------------------------------------------------------------------------------- 12) Type of Reporting Person (See Instructions) OO - -------------------------------------------------------------------------------- 3 1) Names of Reporting Persons I.R.S. Identification Nos. of Above Persons (Entities Only) Merlin BioMed Group LLC - -------------------------------------------------------------------------------- 2) Check The Appropriate Box If a Member of a Group (See Instructions) (A) [ ] (B) [ ] - -------------------------------------------------------------------------------- 3) SEC Use Only - ------------------------------------------------------------------------------ 4) Citizenship or Place of Organization Delaware Limited Liability Company - ------------------------------------------------------------------------------ Number of Shares Beneficially Owned by Each Reporting Person With: 5) Sole Voting Power 0 ----------------------------------------------- 6) Shared Voting Power 1,000,000 ----------------------------------------------- 7) Sole Dispositive Power 0 ----------------------------------------------- 8) Shared Dispositive Power 1,000,000 - ----------------------------------------------------------------------------- 9) Aggregate Amount Beneficially Owned by Each Reporting Person 1,000,000 - ------------------------------------------------------------------------------ 10) Check If the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] - ------------------------------------------------------------------------------ 11) Percent of Class Represented by Amount in Row (9) 6.0% - ------------------------------------------------------------------------------ 12) Type of Reporting Person (See Instructions) IN - ------------------------------------------------------------------------------ 4 Item 1. (a) Name of Issuer: Tapestry Pharmaceuticals, Inc. (b) Address of Issuer's Principal Executive Offices: 4840 Pearl East Circle Suite 300W Boulder, CO 80301 - -------------------------------------------------------------------------------- Item 2. (a) Name of Person Filing: Merlin BioMed Long Term Appreciation, LP Merlin BioMed Offshore Master Fund Merlin BioMed Group LLC (b) Address of Principal Business Office or, if none, Residence: 230 Park Avenue, Suite 928 New York, New York 10169 (c) Citizenship: Merlin BioMed Long Term Appreciation, L.P. is a Delaware Limited Partnership. Merlin BioMed Offshore Master Fund is a Cayman Islands Partnership. Merlin BioMed Group LLC is a Delaware Limited Liability Company. (d) Title of Class of Securities: Common Stock (e) CUSIP Number: 876031204 - -------------------------------------------------------------------------------- Item 3. If this statement is being filed pursuant to Rule 13d-1(b) or (c), or 13d-2(b), check whether the person filing is: (a) [ ] Broker or dealer registered under Section 15 of the Act (b) [ ] Bank as defined in section 3(a)(6) of the Act (c) [ ] Insurance company as defined in section 3(a)(19) of the Act (d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (e) [ ] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E) (f) [ ] An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F) (g) [ ] A parent holding company or control person in accordance with Rule 13d-1(b)(ii)(G) (h) [ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (i) [ ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the 5 Investment Company Act of 1940 (j) [ ] Group, in accordance with 13d-1(b)(1)(ii)(J) Item 4. Ownership: (a) Amount Beneficially Owned: 1,000,000* (b) Percent of Class: 6.0% (c) Number of Shares as to which such person has: (i) Sole power to vote or direct the vote: 0 (ii) Shared power to vote or direct the vote: 1,000,000* (iii) Sole power to dispose or direct the disposition of: 0 (iv) Shared power to dispose or direct the disposition of: 1,000,000* *See Attachment A. - -------------------------------------------------------------------------------- Item 5. Ownership of Five Percent or Less of a Class: If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities check the following [ ] - -------------------------------------------------------------------------------- Item 6. Ownership of More than Five Percent on Behalf of Another Person: Various other persons have the right to receive or the power to direct the receipt of dividends from, or proceeds from sale of, the securities whose ownership is reported on this schedule. No one such other person's interest in such securities relates to more than five percent of the class. - -------------------------------------------------------------------------------- Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on By the Parent Holding Company N/A - -------------------------------------------------------------------------------- Item 8. Identification and Classification of Members of the Group N/A - -------------------------------------------------------------------------------- Item 9. Notice of Dissolution of Group N/A - -------------------------------------------------------------------------------- 6 Item 10. Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Merlin BioMed Long Term Appreciation, L.P. By: Merlin BioMed Group LLC /s/ Norman Schleifer ------------------------------------------------ Name: Norman Schleifer Title: Chief Financial Officer Merlin BioMed Offshore Master Fund By: Merlin BioMed Group LLC /s/ Norman Schleifer ------------------------------------------------ Name: Norman Schleifer Title: Chief Financial Officer By: Merlin BioMed Group LLC /s/ Norman Schleifer ------------------------------------------------ Name: Norman Schleifer Title: Chief Financial Officer Date: May 25, 2006 7 ATTACHMENT A As of April 5, 2006, Merlin BioMed Long Term Appreciation, LP ("Merlin Long Term") and Merlin BioMed Offshore Master Fund ("Merlin Master") are the beneficial owners of 1,000,000 shares of Common Stock of Tapestry Pharmaceuticals, Inc. ("Common Stock"), for a total beneficial ownership of 6.0% of the outstanding shares of Common Stock. As the General Partner of Merlin Long Term and Merlin Master, Merlin BioMed Group LLC has the power to vote and to direct the voting of and the power to dispose and direct the disposition of the 1,000,000 shares of Common Stock owned by Merlin Long Term and Merlin Master. Accordingly, Merlin BioMed Group LLC may be deemed to be the beneficial owner of 1,000,000 shares of Common Stock, or 6.0% of the outstanding shares of Common Stock. ATTACHMENT B AGREEMENT OF JOINT FILING In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with all other persons signatory below of a statement on Schedule 13G or any amendments thereto, with respect to the Common Stock of Tapestry Pharmaceuticals, Inc. and that this Agreement be included as an attachment to such filing. This Agreement may be executed in any number of counterparts each of which shall be deemed to be an original and all of which together shall be deemed to constitute one and the same Agreement. IN WITNESS WHEREOF, the undersigned hereby execute this Agreement on the 25th day of May, 2006. Merlin BioMed Long Term Appreciation, L.P. By: Merlin BioMed Group LLC /s/ Norman Schleifer ------------------------------------------------ Name: Norman Schleifer Title: Chief Financial Officer Merlin BioMed Offshore Master Fund By: Merlin BioMed Group LLC /s/ Norman Schleifer ------------------------------------------------ Name: Norman Schleifer Title: Chief Financial Officer By: Merlin BioMed Group LLC /s/ Norman Schleifer ------------------------------------------------ Name: Norman Schleifer Title: Chief Financial Officer 9 -----END PRIVACY-ENHANCED MESSAGE-----